Season 10 · Episode 17
S10 Ep17: Kang Highlights Considerations for the Integration of Toripalimab into Nasopharyngeal Carcinoma Clinical Practice
OncLive® On Air · OncLive® On Air
February 29, 20248m 49s
Audio is streamed directly from the publisher (audioboom.com) as published in their RSS feed. Play Podcasts does not host this file. Rights-holders can request removal through the copyright & takedown page.
Show Notes
Dr Kang discusses the significance of the FDA approval of toripalimab for nasopharyngeal carcinoma, his anticipated use of the agent since its inclusion on UCSF’s formulary, and the debate around Epstein-Barr virus as a selection criteria for treatment eligibility.